Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience-Reference-Cited by-同舟云学术

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Published:2010-03-27 Issue:6 Volume:24 Page:924-928
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Nozza Silvia,Galli Laura,Visco Francesca,Soria Alessandro,Canducci Filippo,Salpietro Stefania,Gianotti Nicola,Bigoloni Alba,Torre Liviana Della,Tambussi Giuseppe,Lazzarin Adriano,Castagna Antonella

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference7 articles.

1. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

2. Maraviroc for previously treated patients with R5 HIV-1 infection;Gulick;N Engl J Med,2008

3. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial;Madruga;Lancet,2007

4. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial;Lazzarin;Lancet,2007

5. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data;Vingerhoets;Antiv Ther,2008

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regaining virological suppression in a woman living with a six‐class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests;Journal of Medical Virology;2024-07-26

2. The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review;Antiviral Therapy;2023-05-22

3. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

4. Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey;PLOS ONE;2019-11-21

5. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens;HIV Medicine;2017-10-06